OKYO Pharma
  • Home
  • About
    • About
    • Leadership
    • Scientific Advisory Board
    • Directors
  • Disease Focus
    • Neuropathic Corneal Pain
    • Dry Eye Disease
    • Non-infectious Anterior Uveitis
    • Allergic Conjunctivitis 
    • NCP Expanded Access
  • Technology
    • Chemerin Receptor
    • Preclinical Data
  • Pipeline
    • Overview
    • OK-101 Development Timeline
  • Investors
    • Investors
    • Share Information
    • Shareholder Services
    • Investor Presentation
    • SEC Filings
    • Corporate Governance
      • Corporate Documents
      • Corporate Information
      • Corporate Directory
    • FAQs
  • News
    • Press releases
    • Media
  • Contact
  • Linkedin
  • Twitter
Select Page

OKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction

by Paul | 31st October 2023 | News

OKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction Pricing of a registered direct offering for $1.64M of 1,092,600 ordinary shares at an offering price of $1.50 per ordinary share Simultaneous extinguishment of $4.20M of payables by...

OKYO Pharma Limited announces U.S.$5.74 million Global Private Placement and investment by directors and members of senior management

by admin | 14th March 2023 | News

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY...

Recent Posts

  • OKYO Pharma Announces Chairman and Founder Acquires Shares
  • OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain
  • OKYO Pharma Announces Chairman and Founder Acquires Shares
  • OKYO Pharma Announces Chairman and Founder Acquires Shares
  • OKYO Pharma to Present at OIS XV in San Diego

Recent Comments

No comments to show.
OKYO PHARMA

Explore

  • About
  • Disease Focus
  • Technology
  • Pipeline
  • Investors
  • News
  • Contact

Legal

  • Legal
  • Privacy Policy

Follow

  • Follow
  • Follow

© OKYO Pharma, Limited | 2023